Clinical trials: Obesity or Overweight
Overweight, Obesity
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo).
- Trial name
- OASIS 5 (NCT07770841)
- Testing
- Semaglutide
- Where
- 62 sites in United States, Belgium and 8 more
- Volunteers
- 450 people
- Sponsor
- Novo Nordisk A/S
Obesity or Overweight
A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland
The study is investigating weight loss and treatment patterns associated with the use of Saxenda® in adult patients. The aim of the study is to assess the weight loss associated with Saxenda® in patients with obesity or…
- Trial name
- NCT05153590
- Testing
- Saxenda®
- Where
- Denmark
- Volunteers
- 269 people
- Sponsor
- Novo Nordisk A/S
Overweight or Obese
A Study of BGM0504 in Overweight or Obese Participants
The purpose of the study is to evaluate the influence of BGM0504 injection on gastric emptying and Pharmacokinetics of metformin and warfarin in overweight or obese participants
- Trial name
- NCT06920056
- Testing
- Paracetamol, Metformin Hydrochloride, Warfarin
- Where
- China
- Volunteers
- 28 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Obesity, Overweight
AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight
The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week.
- Trial name
- AMAZE 13 (NCT07668401)
- Testing
- Zenagamtide
- Where
- 44 sites in India, Japan and 3 more
- Volunteers
- 400 people
- Sponsor
- Novo Nordisk A/S
Antipsychotic-induced Weight Gain (AIWG)
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese adults with schizophrenia or bipolar disorder treated with…
- Trial name
- GRATITUDE (NCT03818256)
- Testing
- Miricorilant
- Where
- 27 sites in United States
- Volunteers
- 71 people
- Sponsor
- Corcept Therapeutics
Obesity, Knee Osteoarthritis (OA)
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and knee osteoarthritis.
- Trial name
- AMAZE 5 (NCT07481630)
- Testing
- NNC0487-0111
- Where
- 82 sites in United States, Australia and 8 more
- Volunteers
- 400 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3841136 compared with placebo in adult participants with obesity or…
- Trial name
- NCT06230523
- Testing
- Eloralintide
- Where
- 43 sites in United States
- Volunteers
- 263 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
This study will look how well semaglutide tablets taken once daily helps people with body weight above the healthy range. Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily.
- Trial name
- OASIS 4 (NCT05564117)
- Testing
- Semaglutide
- Where
- 23 sites in United States, Canada and 2 more
- Volunteers
- 307 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
ORBERA365 Post-Marketing Clinical Follow-up Study
A prospective, multicenter, open-label, post-approval study of the safety and effectiveness of ORBERA36 as a 12-month adjunct to weight reduction for obese adults (BMI ≥ 27 kg/m2 and BMI ≤ 50 kg/m2) or for pre-surgical weight…
- Trial name
- NCT04362774
- Testing
- ORBERA365
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Apollo Endosurgery, Inc.
Overweight, Prediabetic State
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and…
- Conditions
- Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
- Trial name
- ATTAIN-NOW (NCT07794579)
- Testing
- Orforglipron
- Where
- 180 sites in United States, Argentina and 10 more
- Volunteers
- 2,001 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight and Obesity
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight.
- Trial name
- NCT05051579
- Testing
- LY3502970
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 272 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight and Obesity
Improving Quality of Life in Men and Women With Overweight or Obesity
The purpose of this study is to evaluate the effect of the Noom Healthy Weight Program, a digital behavior change weight loss intervention, on quality of life as measured both by self-report and objective measures, compared to a…
- Conditions
- Obesity, Overweight and Obesity, Quality of Life, Health Behavior
- Trial name
- NCT04871295
- Testing
- Noom Healthy Weight
- Where
- United States
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Noom Inc.
Overweight, Obesity
A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World
This study aims to evaluate the association of once-weekly semaglutide with the risk of cardiovascular (CV) and other obesity-related clinical outcomes in three study populations (Heart failure (HF), clinical Atherosclerotic…
- Conditions
- Overweight, Obesity, Heart Failure (HF), Atherosclerotic Cardiovascular Disease (ASCVD)
- Trial name
- NCT07141914
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 285,327 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The purpose of this study is to identify the weekly oral dose of VRB-101 (oral ecnoglutide) that can effectively maintain body weight in participants with a history of obesity or overweight with weight-related comorbidities.
- Conditions
- Obesity, Overweight, Weight Maintenance
- Trial name
- NCT07553299
- Testing
- VRB-101
- Where
- 20 sites in United States
- Volunteers
- 8 people
- Sponsor
- Verdiva Bio Dev Limited
Weight Loss
VK2735 for Weight Management Phase 3
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics…
- Trial name
- VANQUISH 1 (NCT07104500)
- Testing
- VK2735
- Where
- 137 sites in United States, Puerto Rico
- Volunteers
- 4,500 people
- Sponsor
- Viking Therapeutics, Inc.
Obesity
Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects
To evaluate the weight loss effect and safety of 400 mg velneperit and 120 mg orlistat administered individually or combined three times per day for 24 weeks while on a reduced calorie diet (RCD) and also to evaluate the…
- Trial name
- NCT01126970
- Testing
- Velneperit 400 mg, Orlistat 120 mg, Reduced Calorie Diet
- Where
- 25 sites in United States
- Volunteers
- 486 people
- Sponsor
- Shionogi
Obesity, Overweight
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA)…
- Conditions
- Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea
- Trial name
- TRIUMPH-1 (NCT05929066)
- Testing
- Retatrutide
- Where
- 134 sites in United States, Australia and 10 more
- Volunteers
- 2,335 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Safety and Efficacy Study of HPP404 on Weight Loss in Overweight or Obese Subjects
The purpose of this study is to compare the safety and effect of HPP404 versus placebo on body weight in overweight or obese subjects.
- Trial name
- NCT01540864
- Testing
- HPP404
- Where
- 10 sites in United States
- Volunteers
- 126 people
- Sponsor
- High Point Pharmaceuticals, LLC.
Metabolism and Nutrition Disorder, Obesity
First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity
This trial is conducted in The United States of America. The aim of this trial is to investigate Safety, Tolerability and Pharmacokinetics (the exposure of the trial drug in the body) of NNC0194-0499 in Male Subjects with…
- Trial name
- NCT03015207
- Testing
- NNC0194-0499
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Overweight
A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus
The purpose of this study is to evaluate how fasting and stopping the use of tirzepatide affects the amount of food and drink that stays in the stomach after a meal.
- Conditions
- Diabetes Mellitus, Type 2, Overweight, Obesity
- Trial name
- NCT07299084
- Testing
- Tirzepatide
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Eli Lilly and Company